Wimbledon officials apologise to players after line-calling technology turned off in malfunction on Centre Court - Sky Sports

Most systems are functioning again at five hospitals in Southwestern Ontario after a critical technology malfunction on Saturday morning. The hospitals, Erie Shores Healthcare, Windsor Regional Hospital, Chatham-Kent Health Alliance, Hotel Dieu Grace Healthcare, and Bluewater Health in Sarnia, say it wasn't a hack, and the TransForm Shared Service Organization called it "an extremely rare event. "It caused delays in processing for patient care, including diagnostic imaging. The vendor is working with technical teams from TransForm to restore all systems, but as of Sunday morning, 80 per cent of impacted systems were restored.

Most systems are functioning again at five hospitals in Southwestern Ontario after a critical technology malfunction on Saturday morning. The hospitals, Erie Shores Healthcare, Windsor Regional Hospital, Chatham-Kent Health Alliance, Hotel Dieu Grace Healthcare, and Bluewater Health in Sarnia, say it wasn't a hack, and the TransForm Shared Service Organization called it "an extremely rare event. "It caused delays in processing for patient care, including diagnostic imaging. The vendor is working with technical teams from TransForm to restore all systems, but as of Sunday morning, 80 per cent of impacted systems were restored.

ADVERTISEMENTWindsor WatchFive hospitals in Ontario suffered a technology malfunction over the weekend. They are almost completely back online. August 31, 2026 at 5:13p.m. EDT

News|Articles|October 24, 2026 Baseline and on-treatment circulating tumor DNA (ctDNA) features, including TP53 mutations and methylation-based tumor fraction, were associated with early progression or prolonged progression-free survival (PFS) with first-line lorlatinib (Lorbrena) in patients with ALK-positive advanced non–small cell lung cancer (NSCLC), in exploratory analyses of the phase 3 CROWN trial (NCT03052608) presented at the 2026 European Society for Medical Oncology (ESMO) Congress.1Compared with long-term responders, who were progression free at 84 months (n = 30), early progressors, who had a PFS event within 12 months (n = 22), had a higher median number of altered genes at baseline (10 vs 6), a higher median blood-based tumor mutation burden (7.7 vs 5.1), and more frequent TP53 mutations (50% vs 17%). In the lorlatinib arm, the 7-year PFS rate was 65.0% (95% CI, 54.5%-77.4%) in patients with TP53 wild-type disease (n = 73) vs 40.8% (95% CI, 27.3%-61.1%) in those with TP53-mutated disease (n = 43; HR, 0.48; 95% CI, 0.268-0.857); median PFS was not reached (NR) vs 51.6 months (95% CI, 16.4-NR), respectively.

CML treatment has transformed long-term survival, allowing many patients receiving effective TKI therapy to achieve a life expectancy approaching that of the general population. Molecular response milestones guide personalized treatment decisions, helping clinicians assess treatment effectiveness, recognize inadequate responses, and adjust therapy when necessary.